Boehringer Ingelheim Second Transforming Science Day
World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
Search
Our Expectations
We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
expanded-collaboration-MD-Anderson
The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
Boehringer Ingelheim announces appointments
Boehringer Ingelheim announces appointments
Lothar Halmer
Dr. Lothar Halmer is Chief Quality Officer and leads the Global Quality Organization in providing quality products for our patients every day.
Health Equity: No distance is too far
India is hosting the G20 summit. The leading theme of the G20 summit emphasizes health equity and sustainability as part of the agenda. How we provide access to healthcare for rural areas in India.
Health equity for underserved communities
Introducing initiatives that improve access to healthcare for underserved communities
The power of patient advocacy in cancer care
Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
Facts about the INPULSIS™ trials
R&D - Transforming tomorrow
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it's like working on the cutting edge of pharmaceutical development.
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Open Innovation at Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
We are Global Top Employer 2024
Global Top Employer certification reflects our impactful people development with high scores in development and steering practices as well as benefits on employee wellbeing.
World Recycling Day: Closing the Loop
Transitioning the economy from a linear to a circular approach herculean task – but also an innovation that carries huge potential
Boehringer Olaf Scholz break ground for innovation center
Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
Boehringer receives SBTi validation for CO2 reduction targets
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
Second cancer immunotherapy partnership with 3T Bio
Second cancer immunotherapy partnership with 3T Bio
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
Transforming Science Day
How our ‘patient first’ approach to innovation is aiming to accelerate breakthrough therapies that transform lives. Join our Transforming Science Day.
clinical_collaboration_with_Mirati
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Overcoming stigma and advancing lung cancer advocacy
Lung cancer advocates highlight the need to overcome stigma, access reliable info, and implement early diagnosis and screening.